Good MorningThe major indices held steady on Monday in what was an otherwise uneventful day of trading. The S&P 500 fell about 0.50% on an intraday basis but reclaimed about half of the loss before the close of the session. The day’s action is a sign of caution and not a little indecision. With so much riding on the economic rebound and COVID cases on the rise, a little caution is more than warranted.
This week could be a volatile one for investors. The market is waiting for the next cue and it could come from Congress at any time. Hopes for a bipartisan COVID relief bill continue to grow despite a lack of commitment from Republican leadership. If passed the bill would send another surge of stimulus through the economy but there is another risk as well. That risk is a government shut-down. A stop-gap effort to keep the government running for a week is probably not enough to get the stimulus deal done. If the aid package falls apart like it did before the market could take a dive.
Featured: This tool shows when a stock is about to explode (or collapse) (Ad) 
|
Markets | | | The S&P 500 (NYSEARCA: SPY) is grinding through all-time highs heading into year’s end as the pandemic ravages a third wave in a race for FDA COVID-19 vaccine approvals and distribution. While pundits argue the markets are disconnected with reality, this is the seasonal time of year where ... Read the Full Story |
|
From Our Partners | | Cold War Discovery Could Unlock $100 Trillion in Wealth
Jeff recently traveled to an American ghost town to investigate this crazy Cold War story…
Because it could hold the key to the entire $100 trillion AI boom.
It involves an American ghost town with just 30 people…
And a new twist to the AI boom that could make a lot of people rich. | | Click here to see the details on what could be the biggest tech story of this decade. |
|
Stocks | | | Solid-oxide fuel cell systems provider Bloom Energy (NYSE: BE) stock has seen a resurgence from the electric vehicle (EV) momentum. As momentum and money flow frantically shifts from EVs to EV fueling, power sources and materials, shares of former momentum flyers FuelCell Energy, Inc. (NASDAQ: FCEL)... Read the Full Story |
|
Politics | | | Shares were mixed in Asia on Monday following a report that the U.S. is preparing to slap sanctions on a dozen more Chinese officials, ratcheting up tensions with Beijing.
Benchmarks dropped in Tokyo, Hong Kong and Shanghai but rose in Sydney and Seoul.
China reported... Read the Full Story |
|
From Our Partners | | I made a mistake.
A mistake I feel very foolish about.
After speaking with Donald Trump and some of his advisors, I believed him.
I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years.
But I was wrong. | | Let me show you exactly what we’re doing to prepare. |
|
Markets | | | Chinese vaccine company Sinovac says it is planning to complete a new facility to double its annual vaccine capacity to 600 million doses by the end of the year, while also securing a $500 million investment in a boost to its COVID-19 vaccine efforts Read the Full Story |
|
Markets | | | Industrial production in Germany, Europe's biggest economy, was up 3.2% in October compared with the previous month, according to official data released Monday. It was the second set of figures for October to beat economists' expectations.
The sixth consecutive monthly rise in product... Read the Full Story |
|
From Our Partners | | We’ve got seven great summertime plays for you. These stocks are in a prime position to reward your portfolio… especially if you take action before summer is in full swing!
They cover summer-centric industries such as solar, home improvement, entertainment, travel, and more.
To keep you motivated during these summer months, we’d like to give you a FREE report revealing these companies – 7 Best Stocks to Own in Summer 2025. | | Get Your Copy of "7 Best Stocks to Own in Summer 2025" Here. |
|
Politics | | | SEOUL, South Korea — South Korea has reported 615 new cases of the coronavirus, its 30th day in a row of triple-digit daily jumps, as fears grow the viral spread is getting out of control in the greater capital area.
The country has added more than 5,300 to its caseload just in the pa... Read the Full Story |
|
Politics | | | Shipments of the coronavirus vaccine developed by American drugmaker Pfizer and Germany’s BioNTech were delivered Sunday in the U.K. in super-cold containers, two days before it goes public in an immunization program that is being closely watched around the world.
Around 800,000 doses... Read the Full Story |
|
Markets | | | Smith & Wesson Brands (NASDAQ:SWBI) reported a fantastic fiscal 2nd quarter and it looks like these gains could stick. Based on the number of federal background checks and the number of 1st-time buyers Read the Full Story |
|
Markets | | | “Work-from-home,” “exercise-from-home,” and “shop-from-home” were among the big winners in the coronavirus, and for Teladoc Health (NYSE:TDOC), “see-the-doctor-at-home” proved to be one of the biggest slam-dunks around. Read the Full Story |
|
Markets | | | A Changing Landscape For Mall-Based RetailersThe mall-based brick&mortar retail industry has been on the rocks for years. The pandemic didn’t cause this problem it only accelerated a shift to digital and non-mall retailers that was already in place. What this means for many mall-based reta... Read the Full Story |
|
The Early Bird Stock Of The Day Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. | | View Today's Stock Pick |
|
